Compare PGC & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | SLDB |
|---|---|---|
| Founded | 1921 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.9M | 464.1M |
| IPO Year | N/A | 2018 |
| Metric | PGC | SLDB |
|---|---|---|
| Price | $29.70 | $5.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $35.33 | $14.82 |
| AVG Volume (30 Days) | 174.9K | ★ 987.6K |
| Earning Date | 01-27-2026 | 11-03-2025 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 6.12 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $248,809,000.00 | N/A |
| Revenue This Year | $27.34 | N/A |
| Revenue Next Year | $16.59 | N/A |
| P/E Ratio | $15.37 | ★ N/A |
| Revenue Growth | ★ 18.63 | N/A |
| 52 Week Low | $23.96 | $2.41 |
| 52 Week High | $36.27 | $7.37 |
| Indicator | PGC | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 71.44 | 60.44 |
| Support Level | $27.80 | $5.47 |
| Resistance Level | $28.34 | $6.04 |
| Average True Range (ATR) | 0.63 | 0.34 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 91.93 | 73.98 |
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Wealth Management Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and Internet banking services. Wealth Management includes investment management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services. The services provided by the company include checking and savings accounts, money market and interest-bearing checking accounts, certificates of deposit, individual retirement accounts, and other services.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.